Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis

Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis

Resource Type

CF Research News

Authors

Elizabeth Baker, William T Harris, Steven M Rowe, Sarah B Rutland, Gabriela R Oates

References

J Cyst Fibros. 2020 Oct 3;S1569-1993(20)30870-5. doi: 10.1016/j.jcf.2020.09.011. Online ahead of print.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

CFTR modulators [3]
Secondhand smoke [4]
Smoke exposure [5]
Tezacaftor/ivacaftor [6]
Tobacco [7]

Date

Saturday, October 3, 2020

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/tobacco-smoke-exposure-limits-therapeutic-benefit

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-20-00179R1_FINAL_Oates_311020.pdf [2] https://pubmed.ncbi.nlm.nih.gov/33023836/ [3] https://www.ecfs.eu/research-article-keywords/cftr-modulators [4] https://www.ecfs.eu/research-article-keywords/secondhand-smoke [5] https://www.ecfs.eu/research-article-keywords/smoke-exposure [6] https://www.ecfs.eu/research-article-keywords/tezacaftorivacaftor [7] https://www.ecfs.eu/research-article-keywords/tobacco [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines